TG Therapeutics, Inc. (TGTX) Stock Price Up 0%
Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) rose 0% during mid-day trading on Thursday . The stock traded as high as $8.60 and last traded at $8.30. Approximately 1,864,748 shares traded hands during mid-day trading, an increase of 11% from the average daily volume of 1,675,642 shares. The stock had previously closed at $8.30.
TGTX has been the topic of several research analyst reports. BidaskClub upgraded shares of TG Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 16th. ValuEngine lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $28.00 target price on shares of TG Therapeutics in a research report on Tuesday, October 3rd. Finally, Zacks Investment Research lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $25.11.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.05). The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 155.38% and a negative net margin of 73,217.77%. research analysts predict that TG Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of TGTX. Bank of New York Mellon Corp boosted its position in TG Therapeutics by 40.7% during the first quarter. Bank of New York Mellon Corp now owns 271,879 shares of the biopharmaceutical company’s stock worth $3,168,000 after acquiring an additional 78,644 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in TG Therapeutics during the first quarter worth about $1,291,000. Parametric Portfolio Associates LLC purchased a new position in TG Therapeutics during the first quarter worth about $928,000. JPMorgan Chase & Co. raised its stake in TG Therapeutics by 619.5% during the first quarter. JPMorgan Chase & Co. now owns 252,870 shares of the biopharmaceutical company’s stock worth $2,946,000 after purchasing an additional 217,724 shares during the period. Finally, American International Group Inc. raised its stake in TG Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 22,681 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 1,500 shares during the period. Hedge funds and other institutional investors own 49.94% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/11/tg-therapeutics-inc-tgtx-stock-price-up-0.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.